Frank Isaksson, GM for Taiwan, commented on this growth stating: "Demand for auto injectors continues to rise as the number of biologics coming to market steadily increases. The simple fact is that SHL will continue to expand our production capabilities over the next few years and will also find new ways to enhance our utilization of current machinery, people and resources. Several of our biotechnology and pharmaceutical customers are now working with us on multiple projects. With continued expansion in Taiwan, our new facility in the USA and future expansion in Europe we will have the depth of capabilities and resources needed to maintain our leadership position in the auto injector market, including production of other drug delivery devices such as pen injectors and inhalers systems."
SHL currently has six production facilities in Taiwan related to SHL Medical and plans to acquire space at two of its larger facilities as needed. Further expansion related to production facilities has also taken place in North America with SHL’s newest facility based in South Florida focusing on the final packaging and assembly of drug delivery devices, such as the Molly Auto Injector. SHL will continue to develop additional in-house capabilities to further enhance the range of services we can offer to our clients.